de Winter, Derek P.
Kaminski, Allysen
Tjoa, May Lee
Oepkes, Dick
Lopriore, Enrico
Article History
Received: 12 October 2022
Accepted: 11 October 2023
First Online: 18 October 2023
Declarations
:
: Not applicable.
: Not applicable.
: D.P. de Winter, PhD candidate, is funded by Momenta Pharmaceuticals, Inc., which was acquired by Johnson & Johnson and is a coordinating investigator for a phase 2 trial (NCT03842189) of a new drug for the treatment of HDFN, which is sponsored by Janssen Pharmaceuticals.Allysen Kaminski was a former employee of OPEN Health, which was retained by Janssen Pharmaceuticals to conduct the study.May Lee Tjoa is an employee and stockholder of Janssen Pharmaceuticals.Dick Oepkes was during the development and execution of the current study the principial investigator for a phase 2 trial (NCT03842189) of a new drug for the treatment of HDFN, which is sponsored by Janssen Pharmaceuticals.Enrico Lopriore is a sub-investigator for a phase 2 trial (NCT03842189) of a new drug for the treatment of HDFN, which is sponsored by Janssen Pharmaceuticals.